US Patent 12006314 Anti-cancer nuclear hormone receptor-targeting compounds
Patent 12006314 was granted and assigned to Nuvation Bio on June, 2024 by the United States Patent and Trademark Office.
Name
# Contributions
Last Contribution
Find more entities like US Patent 12006314 Anti-cancer nuclear hormone receptor-targeting compounds
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
By using this site, you agree to our Terms of Service.